Skip to main content Accessibility help
×
Hostname: page-component-77c89778f8-vpsfw Total loading time: 0 Render date: 2024-07-17T14:01:19.977Z Has data issue: false hasContentIssue false

66 - Galantamine

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Razadyne, Razadyne ER, Reminyl

Generic?

• Yes

Class

• Cholinesterase inhibitor

Commonly Prescribed for

(FDA approved in bold)

Alzheimer's dementia (AD) (mild or moderate)

• Dementia with Lewy bodies (DLB)

• Vascular dementia

How the Drug Works

• Increases the concentration of acetylcholine through reversible inhibition of metabolism by acetylcholinesterase enzyme, which increases availability of acetylcholine. A deficiency of cholinergic function is felt to be important in producing the signs and symptoms of AD

• May also modulate nicotine receptors thereby increasing acetylcholine release

• May interfere with amyloid deposition

• Although symptoms of AD can improve, galantamine does not prevent disease progression

How Long Until It Works

• Typically 2–6 weeks at a given dose, but effect is best observed over a period of months

If It Works

• Continue to use but symptoms of dementia usually worsen over time

If It Doesn't Work

• Consider adjusting dose

• Change to another cholinesterase inhibitor or NMDA antagonist (memantine)

• Non-pharmacological measures are the basis of dementia treatment. Maintain regular schedules and routines. Avoid prolonged travel, unnecessary medical procedures or emergency room visits, crowds, and large social gatherings

• Limit drugs with sedative properties such as opioids, hypnotics, AEDs, and TCAs

• Treat other disorders that can worsen symptoms, such as hyperglycemia or urinary difficulties

Best Augmenting Combos for Partial Response or Treatment-Resistance

• Addition of the NMDA receptor antagonist memantine may be useful

• Treat depression or apathy with SSRIs but be cautious for increased risk of AEs (e.g., QTc prolongation, injurious falls). Avoid TCAs in demented patients due to risk of confusion. In dementia patients with severe depression, electroconvulsive therapy can be an option

• For significant confusion and agitation avoid neuroleptics (especially in DLB) because of the risk of neuroleptic malignant syndrome. Atypical antipsychotics (e.g., risperidone, clozapine, aripiprazole) or SSRIs can be used instead

Tests

• None required

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 243 - 246
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Galantamine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.067
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Galantamine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.067
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Galantamine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.067
Available formats
×